Remission of psoriasis after allogeneic, but not autologous, hematopoietic stem-cell transplantation - 09/02/13
, Henry K. Wong, MD, PhD a, Wael Jarjour, MD b, Leslie A. Andritsos, MD c
Reprint requests: Benjamin H. Kaffenberger, MD, Dermatology, Ohio State University, 540 Officenter Place, Gahanna, OH 43216.Abstract |
Hematopoietic stem-cell transplantation (HSCT) has emerged as an effective immunotherapy for several severe autoimmune diseases. A comprehensive search of the existing literature was performed for patients with psoriasis and HSCT. Nineteen patients have been reported to have psoriasis resolution after allogeneic or autologous HSCT. In the allogeneic setting, 10 of 13 were noted to have durable remission of their psoriasis with a mean follow-up of 49 months. Two cases that did reoccur were only transient. Six patients underwent autologous transplantation. Of these, 5 of 6 developed a recurrence of their psoriasis within 2 years. Based on a limited number of patients, psoriasis is likely to remit after allogeneic HSCT, but it is likely to recur after autologous HSCT.
Le texte complet de cet article est disponible en PDF.Key words : allogeneic, autologous, bone-marrow transplant, cancer, hematopoietic stem-cell transplantation, immunotherapy, medical dermatology, psoriasis vulgaris
Plan
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
Vol 68 - N° 3
P. 489-492 - mars 2013 Retour au numéro
Article précédent
- Diffuse melanosis cutis: A systematic review of the literature
- Deshan F. Sebaratnam, Supriya S. Venugopal, John W. Frew, James R. McMillan, Eve R. Finkelstein, Linda K. Martin, Dédée F. Murrell
- Large congenital melanocytic nevi: Therapeutic management and melanoma risk : A systematic review
- Morgane Vourc’h-Jourdain, Ludovic Martin, Sébastien Barbarot, aRED
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?